OverviewSuggest Edit

ProtoKinetix is a bio-technology company that provides medical researchers with a platform for enhancing cell survival and health, both in vitro and in vivo. At the heart of its technology is its patented anti-aging glycopeptide AAGP. This small molecule (580 Daltons) displays abilities in resolving challenges confronting medical researchers in such areas as regenerative medicine and as a therapy for diseases relating to tissue inflammation and oxidation stress. Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. Further, it can function without toxic side effects common in treatments involving larger and less stable compounds.

TypePublic
Founded1999
HQMarietta, OH, US
Websiteprotokinetix.com

Latest Updates

Revenue (FY, 2014)$0
Share Price (Jan 2021)$0.1 (+20%)
Cybersecurity ratingCMore

Key People/Management at ProtoKinetix

Clarence E. Smith

Clarence E. Smith

Chairman, President, Director
Edward P. McDonough

Edward P. McDonough

Director
Michael R. Guzzetta

Michael R. Guzzetta

Chief Financial Officer
Julia Levy

Julia Levy

Chairman, Business and Scientific Advisory Board
Show more

ProtoKinetix Office Locations

ProtoKinetix has an office in Marietta
Marietta, OH, US (HQ)
412 Mulberry St
Show all (1)

ProtoKinetix Financials and Metrics

ProtoKinetix Revenue

USD

Net income (Q3, 2020)

(1.7m)

Market capitalization (25-Jan-2021)

36.7m

Closing stock price (25-Jan-2021)

0.1

Cash (30-Sept-2020)

44.8k
ProtoKinetix's current market capitalization is $36.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

201.0k119.4k95.8k141.5k126.8k99.6k105.3k78.1k280.4k

R&D expense

117.4k74.5k13.8k158.9k450.9k296.5k337.1k369.5k

Operating expense total

318.4k119.4k170.3k155.3k285.7k550.5k401.8k415.1k650.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

General and administrative expense

44.3k28.6k34.4k28.7k29.6k20.9k26.0k23.3k14.1k49.0k21.0k38.9k42.7k23.2k21.4k29.5k17.3k32.1k29.8k12.5k17.4k25.6k13.7k33.9k91.4k76.9k57.0k71.0k46.5k

R&D expense

13.4k18.3k18.3k18.3k12.9k2.1k53.0k19.1k29.9k71.7k108.5k175.0k69.0k86.2k72.9k84.6k70.5k92.8k63.5k74.7k140.9k219.5k76.8k142.2k

Operating expense total

44.3k42.0k34.4k28.7k29.6k39.1k44.2k41.6k26.9k49.0k23.1k91.9k61.8k53.1k93.1k138.0k192.3k101.2k116.0k85.4k102.1k96.1k106.5k97.4k166.1k217.8k276.5k147.8k188.7k
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.5k2.4k3.1k317.0371.1k371.0k302.9k136.0k377.3k

Accounts Receivable

6.5k6.0k119.05.5k8.0k

Prepaid Expenses

18.7k21.5k397.062.1k1.1k1.1k

Current Assets

379.5k441.4k365.1k137.1k378.4k
Quarterly
Show all financial metrics

ProtoKinetix Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

ProtoKinetix Online and Social Media Presence

Embed Graph

ProtoKinetix Blogs

Why Dr. Asim Raja believes in the potential of AAGP

Imagine the ability to fully recover from Type 1 diabetes and no longer live your life according to insulin. Imagine a future where we can overcome blindness. AAGP, the glycopeptide developed by ProtoKinetix, has the power to transform regenerative medicine, paving the path toward incredible medical…

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

Marietta, Ohio, November 24, 2020                                                                                           ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a rese…

Biotech Investing: How to Pick a Winner

The promise of biotechnology stocks to the average investor is the potential for blazing growth and incredible returns. But not every company pays dividends on that promise. Too many times, investors have been burned by biotech stocks that burn fast and bright before completely flaming out. What the…

AAGP’s role in islet cell transplants

The post AAGP’s role in islet cell transplants appeared first on ProtoKinetix.

Dry Eye Disease: Investor Presentation

Dry eye disease (DED) is a multifactorial disease of the ocular surface which results in a spectrum of symptoms and/or signs that affect 5 30% of the population. Download our dry eye disease investors deck to learn how Protokinetix is creating biotechnology that can help change the future of how we …

Seeking improved treatments for dry eye disease

A 2017 study from the American Optometric Association found that more than 16 million Americans are affected by dry eye disease (DED), also known as dry eye syndrome (DES), including nearly twice as many women as men. There is no single cause for eye dryness. It can be temporary or chronic and resul…

ProtoKinetix Frequently Asked Questions

  • When was ProtoKinetix founded?

    ProtoKinetix was founded in 1999.

  • Who are ProtoKinetix key executives?

    ProtoKinetix's key executives are Clarence E. Smith, Edward P. McDonough and Michael R. Guzzetta.

  • Who are ProtoKinetix competitors?

    Competitors of ProtoKinetix include International Stem Cell Corporation, EpiVax and Transgene.

  • Where is ProtoKinetix headquarters?

    ProtoKinetix headquarters is located at 412 Mulberry St, Marietta.

  • Where are ProtoKinetix offices?

    ProtoKinetix has an office in Marietta.

  • How many offices does ProtoKinetix have?

    ProtoKinetix has 1 office.